Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06128278 · ClinicalTrials.gov registry record · Phase 2
Acute Equol Supplementation and Vascular Function in Women With and Without CKD
A Phase 2 study of Chronic Kidney Diseases and Women, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT06128278 is a Phase 2 study of Chronic Kidney Diseases and Women that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 38 participants, below the 444-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06128278, a Phase 2 study of Chronic Kidney Diseases and Women, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
The risk of cardiovascular disease (CVD) is significantly elevated in patients with chronic kidney disease (CKD). Notably, women with CKD commonly experience menstrual disturbances induced by CKD, which may contribute to impaired vascular function and elevated CVD risk. However, most of the literature in nephrology focuses on male patients, and studies on women's vascular health are limited. Establishing effective therapies for improving vascular function and reducing CVD risk in women with CKD is a high research priority of the NIH. Equol contributes to improvement in vascular function, mediated in part by its anti-oxidative and anti-inflammatory properties. However, there is no information on the effect of equol on vascular function in women with CKD. The proposed project aims to determine the acute effect (1-hour, 2-hours, and 3-hours post ingestion) of oral equol supplementation on vascular function in postmenopausal women with and without CKD.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG S-equol
Study Locations (1)
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2023-03-07 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06128278
The ClinicalTrials.gov registry entry for NCT06128278 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 444-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (91% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Chronic Kidney Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06128278 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT06128278 about?
NCT06128278 is a clinical study titled "Acute Equol Supplementation and Vascular Function in Women With and Without CKD". The risk of cardiovascular disease (CVD) is significantly elevated in patients with chronic kidney disease (CKD). Notably, women with CKD commonly experience menstrual disturbances induced by CKD, which may contribute to impaired vascular function and elevated CVD risk. However, most of the literatu...
What is the current status of trial NCT06128278?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2023-03-07. Estimated completion is 2026-12-31.
What conditions does trial NCT06128278 study?
This clinical trial studies the following conditions: Chronic Kidney Diseases, Women, Vascular Function.
What interventions are being tested in trial NCT06128278?
The interventions under investigation include: Placebo (OTHER), S-equol (DRUG).
Who is sponsoring clinical trial NCT06128278?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06128278 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
RECRUITING · Phase 2
-
Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine
RECRUITING · Phase 2
-
Ferric Citrate and Chronic Kidney Disease in Children
RECRUITING · Phase 2
-
Bone in CKD Alkali Response (BICARb Pilot Trial)
RECRUITING · Phase 2
-
Combination of Novel Therapies for CKD Comorbid Depression
RECRUITING · Phase 2
-
Sit Less, Interact and Move More (SLIMM) 2 Study
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.